फुफ्फुसाचा कर्करोग (non-small cell)
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
कुठे जायचं
भारतातील 13 hospitals या trial साठी रुग्णांना घेत आहेत.
रजिस्ट्री सारांश (तांत्रिक)
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.
Sponsor: Mirati Therapeutics Inc.
NCT04613596 on ClinicalTrials.gov
Last updated on the registry 13 Oct 2026 · read by us 20 Oct 2026